175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
Titel:
175P Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
Auteur:
Cardoso, F. Juric, D. Lerebours, F. Krop, I. Ruiz Borrego, M. Neven, P. Park, Y.H. Yardley, D. Jhaveri, K. Arce, C. Gu, E. Akdere, M. Rugo, H.S.